Close Menu

This article has been updated from a previous version to include comments made by NeoGenomics executives during the company's earnings call.

NEW YORK – NeoGenomics on Thursday reported a 40 percent year-over-year jump in its Q4 revenues.

The cancer genetic testing company reported revenues of $106.9 million for the three-month period ended Dec. 31, 2019, up from revenues of $76.5 million in the same period last year and beating the consensus Wall Street estimate of $104.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.